Clear Labels for Cultivated and Plant Proteins

Summary#

This bill sets new definitions and labeling rules for cell‑cultivated meat and poultry and for plant‑based products that look like meat. It requires the Department of Agriculture (USDA) and Health and Human Services (HHS)/Food and Drug Administration (FDA) to update their agreement on who regulates what. The stated goal is to help consumers make informed choices by forcing clearer labels and by bringing cell‑cultivated products under meat and poultry inspection laws.

• New definitions: Creates legal definitions for “cell‑cultivated protein product” (for meat and poultry) and “plant‑based alternative protein product.”
• Labeling rules: Requires labels for cell‑cultivated products to show the words “cell‑cultivated,” say they are derived from sources other than meat/poultry, and state they do not contain naturally produced meat or live birds. Plant‑based products must be labeled “plant‑based alternative protein product” and say they are not derived from naturally produced meat or poultry.
• Inspection and law coverage: Applies the Federal Meat Inspection Act and the Poultry Products Inspection Act to cell‑cultivated products in the same way they apply to conventional meat and poultry.
• Agency roles: Directs USDA to implement these changes and directs HHS/FDA to handle premarket review of cell collection, cell banks, production materials, and some facility controls and inspections.
• Standards of identity: Requires USDA and HHS/FDA to develop common standards of identity for both cell‑cultivated and plant‑based products within 180 days.

What it means for you#

• Producers of cell‑cultivated meat or poultry:

  • Must use the new legal term and follow the labeling requirements.
  • Their products will be covered by the same meat or poultry inspection laws as conventional products.
  • They will face premarket review of cell lines, cell banks, inputs, and some manufacturing controls by HHS/FDA.
  • They may need to register facilities and meet good manufacturing practices and preventive controls under FDA rules, and respond to inspections.

• Producers of plant‑based meat alternatives:

  • Must label products as “plant‑based alternative protein product” followed by the food name.
  • Must include a clear statement that the product is not derived from naturally produced meat or poultry.

• Retailers and food service:

  • Will need to display and sell products with the required labels.
  • May need to relabel existing inventory to comply.

• Consumers:

  • Labels on cell‑cultivated and plant‑based products must more clearly state how the product was made and that it does not contain naturally produced meat or live birds.
  • This should make it easier to distinguish conventional meat from alternative products at the point of purchase.

• Federal agencies:

  • USDA will carry out the law changes for inspection and labeling.
  • HHS/FDA will perform premarket review and certain facility oversight tasks related to cell culture and production inputs.

Expenses#

No direct public cost estimate is included in the bill text or the provided materials.

• No publicly available information.
• Possible costs the bill implies (not estimated in the bill):
  • Administrative and inspection costs for USDA and HHS/FDA to implement new oversight and carry out additional inspections.
  • Compliance costs for producers to change labels, meet inspection rules, register facilities, and satisfy premarket review.
  • Possible costs for retailers to relabel inventory and update point‑of‑sale materials.

Proponents' View#

• The bill appears intended to make labels clearer so consumers can tell conventional meat and poultry apart from cell‑cultivated and plant‑based products.
• It would likely standardize how alternative proteins are described across federal law by creating definitions and standards of identity.
• Bringing cell‑cultivated products under meat and poultry inspection laws could be seen as creating consistent food‑safety and inspection treatment between conventional and cell‑cultivated products.
• Assigning specific premarket and facility oversight tasks to HHS/FDA aims to ensure that biological materials and cell‑growth processes are reviewed for safety before products reach the market.

Opponents' View#

• One concern is that the bill does not fully explain how USDA and HHS/FDA will divide inspection and enforcement duties in practice; the overlap could cause confusion or duplication.
• The requirements to apply meat and poultry inspection rules to cell‑cultivated products may increase regulatory burdens and costs for producers, especially small firms.
• Labels required by the bill might be argued to stigmatize or disadvantage alternative products in the marketplace; the bill does not discuss marketing impacts.
• The 180‑day deadline to develop standards of identity is short; it may be difficult for agencies to consult, draft, and finalize consistent standards in that time.
• The bill provides no fiscal note, so the scale of agency staffing, inspection, and enforcement costs is unclear.